Pluristem Therapeutics to Raise $3.0 Million in Registered Direct Offering

• Press Release
• Source: Pluristem Therapeutics Inc.
• On 9:55 am EDT, Tuesday October 6, 2009

HAIFA, Israel--(BUSINESS WIRE)--Pluristem Therapeutics Inc.. (NasdaqCM:PSTI) (DAX:PJT) today announced that it has entered into definitive agreements with selected institutional investors to sell common stock and warrants for aggregate gross proceeds of approximately $3.0 million, before deducting placement agent fees and estimated offering expenses. The offering includes 2,702,822 shares of common stock and warrants to purchase 1,081,129 shares of common stock. The price per share of Common Stock is $1.12, and the exercise price of the warrants is $1.60. The Warrants will be exercisable for a period of five years commencing six months following the issuance thereof. The closing is scheduled to take place no later than October 12, 2009.

Related Quotes

Symbol	Price	Change
PSTI	1.01	-0.01

{"s" : "psti","k" : "c10,l10,p20,t10","o" : "","j" : ""}

The offering is made pursuant to the Form S-3 shelf registration statement that was filed by Pluristem with the Securities and Exchange Commission (the “SEC”) and declared effective by the SEC on July 1, 2008. The offering is expected to close on or about October 12, 2009, subject to the satisfaction of customary closing conditions.

Roth Capital Partners, LLC acted as the exclusive placement agent for the offering.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. Any offer will be made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. Copies of the prospectus supplement together with the accompanying prospectus can be obtained at the SEC’s website at http://www.sec.gov or from Roth Capital Partners, 24 Corporate Plaza Drive, Newport Beach, CA, 92660, attention: Equity Capital Markets.

About Pluristem

Pluristem is a clinical stage biotechnology company with proprietary technology for the development and manufacturing of standardized cell therapies derived from the human placenta. Pluristem’s patented and scalable PLX (PLacental eXpanded) cell product candidates are developed as readily available for the treatment of critical limb ischemia (CLI) and other diseases.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. For example, when we discuss our intentions regarding the use of funds raised, we are using forward-looking statements. These forward-looking statements are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; results in the laboratory may not translate to equally good results in real surgical settings; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risk and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission.

For more information visit our website at www.pluristem.com, the content of which is not part of this press release.

Pluristem Therapeutics Inc.
William Prather RPh, MD, +1-303-883-4954
Sr. VP Corporate Development
William.PratherMD@pluristem.com
or
Russo Partners
Andreas Marathovouniotis, +1-212-845-4235
andreas.marathis@russopartnersllc.com